The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

A group that’s been working on the front lines of the opioid crisis since 2017 holds its first-ever winter gala at The Hall ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

Talking with the North Carolina Harm Reduction Coalition’s Loftin Wilson about the coalition’s work, how the opioid epidemic ...